Personal factors

A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapies. The team is also developing an algorithm to predict the likelihood of antibody development against other recombinant protein-based therapies.¹ Based on the results, one of the investigators has cofounded Haplomics Inc. to develop new factor VIII replacement therapies.

Hemophilia A is caused by inherited alterations in the F8 gene that encodes factor VIII, a critical component of the coagulation cascade. Standard of care for the disease is treatment with plasma-derived or recombinant factor VIII protein...